meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anticoagulant
anticoagulant, curative dose
anticoagulant, pre-admission
anticoagulant, prophylactic dose
anticoagulation, intermediate prophylactic dose
Bivalirudin
enoxaparin
heparin at therapeutic dose
P2Y12 inhibitors
rivaroxaban
sulodexide
face mask
febuxostat
hydrogen-oxygen nebulizer
hyperbaric oxygen
nintedanib
paracetamol
pulmonary rehabilitation
respiratory support
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
potential COVID-19 treatments
adjuvant therapies
anticoagulant
anticoagulant, curative dose
anticoagulant, prophylactic dose
antiviral and associated therapy
chloroquine and derivatives
hydroxychloroquine
control
standard of care
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
healthcare workers
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Li [retracted], 2020
-
cancelled by investigator
Li W, Xiong J, Guo Y, Lip GYH.
Preprints 2020 [retracted]